Domestic revenues were $37.4 million for the third quarter and $105.4 million for the first nine months of 2009, both representing increases of 12 percent over the same periods the year before.
Third-quarter revenues reflect the launch of four new orthopedic implants and revenue for the first nine months reflects new revenues from Tutogen, which merged with RTI.
Read the release on RTI Biologics third-quarter revenue.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
